Assessment of striatal and extrastriatal [18F]fluoroDOPA uptake by a Silicon Photomultiplier PET camera in Parkinson's disease [0.03%]
帕金森病中[18F]氟多巴在黑质外区域的摄取分布及硅光电倍增管PET显像评估
Jacques Darcourt,Pierre-Malick Koulibaly,Aurélie Schiazza et al.
Jacques Darcourt et al.
Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein [0.03%]
针对成纤维活化蛋白的预临床治疗诊断研究：结合[177Lu]Lu-FAPI-2286和培唑帕尼在肉瘤模型中的抗肿瘤活性
Jin-Ren Tseng,Cheng-Lung Hsu,Hsin-Hua Hsieh et al.
Jin-Ren Tseng et al.
Harmonized quantitative bone SPECT/CT parameters for risk assessment of medication-related osteonecrosis of the jaw: multicenter study [0.03%]
多中心研究建立的药物相关性颌骨坏死风险评估的规范化定量骨SPECT/CT参数
Kazuhiro Kitajima,Yu Iwabuchi,Yoshitaka Inui et al.
Kazuhiro Kitajima et al.
Enhancing reader confidence through dual-time imaging and alternative reconstruction algorithms with [18F]PSMA-1007 PET/CT imaging in local relapsed castration-sensitive prostate cancer? [0.03%]
通过双时相成像和替代重建算法提高读者信心以进行[18F]PSMA-1007 PET/CT成像局部复发的雄激素剥夺治疗敏感性前列腺癌？
Emil Novruzov,Gabriel Sheikh,Anna Feisthauer et al.
Emil Novruzov et al.
A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer [0.03%]
一项关于镥[177Lu]PSMA-617放射配体治疗在中国前列腺癌进展患者的二期研究：药代动力学和剂量学评估
Hongcheng Shi,Jianming Guo,Wei Fan et al.
Hongcheng Shi et al.
Evaluation of ultrasonographic and clinicopathological features of patients with abnormal [68Ga]Ga-DOTA-TATE uptake in the thyroid gland [0.03%]
甲状腺异常摄取[68Ga]Ga-DOTA-TATE患者的超声和临床病理特征分析
Beril Turan Erdogan,Fatma Dilek Dellal Kahramanca,Gulsum Karaahmetli et al.
Beril Turan Erdogan et al.
Automated RECOMIA AI-based total metabolic tumor volume in lymphoma - a retrospective study [0.03%]
基于人工智能的淋巴瘤全面代谢肿瘤体积(RECOMIA AI)的自动化研究-一项回顾性研究
May Sadik,Johanna Mörk,Jesus Lopez Urdaneta et al.
May Sadik et al.
Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE [0.03%]
基于SPECT/CT显像的吸收剂量与标准摄取值(SUV)与神经内分泌肿瘤患者接受[¹⁷⁷Lu]Lu-DOTA-TATE治疗相关量效关系的研究
Fei Liu,Hongxing Yang,Jianping Zhang et al.
Fei Liu et al.
Background: The aim of this study was to evaluate the efficacy of neuroendocrine neoplasms (NENs) patients treated with peptide receptor radionuclide therapy (PRRT), and to investigate the relationships among the absorbed...
Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression [0.03%]
剂量分析表明[¹⁷⁷Lu]Lu-PSMA-617在高PSMA表达的非前列腺癌中的清除迅速且吸收剂量较低
Fadi Khreish,Florian Rosar,Caroline Burgard et al.
Fadi Khreish et al.
Predicting overall survival in pancreatic ductal adenocarcinoma using 18F-FDG PET/CT radiomics: a two-center study [0.03%]
基于~(18)F-FDG PET/CT 影像组学的胰腺导管腺癌患者总生存期预测：多中心研究
Yang Xu,Yunmei Shi,Tao Jiang et al.
Yang Xu et al.